Latest Insider Transactions at Aclaris Therapeutics, Inc. (ACRS)
This section provides a real-time view of insider transactions for Aclaris Therapeutics, Inc. (ACRS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aclaris Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aclaris Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 17
2022
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.7%
|
$75,000
$15.98 P/Share
|
|
Oct 07
2022
|
Andrew N Schiff |
SELL
Open market or private sale
|
Indirect |
7,324
-1.24%
|
$117,184
$16.16 P/Share
|
|
Oct 06
2022
|
Andrew N Schiff |
SELL
Open market or private sale
|
Indirect |
37,839
-6.04%
|
$605,424
$16.54 P/Share
|
|
Oct 04
2022
|
Andrew N Schiff |
SELL
Open market or private sale
|
Indirect |
7,700
-1.21%
|
$123,200
$16.01 P/Share
|
|
Jun 17
2022
|
Andrew N Schiff |
SELL
Open market or private sale
|
Direct |
19,565
-100.0%
|
$293,475
$15.14 P/Share
|
|
Jun 03
2022
|
Maxine Gowen |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+30.1%
|
-
|
|
Jun 03
2022
|
William D. Humphries |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+14.64%
|
-
|
|
Jun 03
2022
|
Anand Mehra |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+8.94%
|
-
|
|
Jun 03
2022
|
Vincent Milano |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+50.0%
|
-
|
|
Jun 03
2022
|
Christopher P. Molineaux |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+10.97%
|
-
|
|
Jun 03
2022
|
Andrew Kenneth William Powell |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+19.5%
|
-
|
|
Jun 03
2022
|
Bryan M. Reasons |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+14.64%
|
-
|
|
Jun 03
2022
|
Andrew N Schiff |
BUY
Exercise of conversion of derivative security
|
Direct |
3,356
+14.64%
|
-
|
|
May 16
2022
|
Andrew Kenneth William Powell |
SELL
Bona fide gift
|
Direct |
709
-6.33%
|
-
|
|
Apr 25
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
20,000
-1.58%
|
$300,000
$15.18 P/Share
|
|
Apr 22
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.94%
|
$375,000
$15.04 P/Share
|
|
Apr 21
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
25,000
-1.9%
|
$375,000
$15.24 P/Share
|
|
Apr 18
2022
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,000
-22.0%
|
$480,000
$16.28 P/Share
|
|
Mar 11
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
56,303
-4.1%
|
$844,545
$15.91 P/Share
|
|
Mar 10
2022
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
27,165
-16.61%
|
$407,475
$15.71 P/Share
|
|
Mar 10
2022
|
Frank Ruffo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,823
-5.97%
|
$192,345
$15.55 P/Share
|
|
Mar 02
2022
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,254
+1.31%
|
-
|
|
Mar 02
2022
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,297
+3.72%
|
-
|
|
Mar 02
2022
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+7.1%
|
-
|
|
Mar 01
2022
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
114,425
+4.02%
|
-
|
|
Mar 01
2022
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,050
+7.68%
|
-
|
|
Mar 01
2022
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,750
+18.42%
|
-
|
|
Feb 09
2022
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
3,595
-0.29%
|
$43,140
$12.66 P/Share
|
|
Feb 09
2022
|
Frank Ruffo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,388
-0.8%
|
$16,656
$12.66 P/Share
|
|
Feb 09
2022
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
383
-0.44%
|
$4,596
$12.68 P/Share
|
|
Feb 01
2022
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+0.86%
|
-
|
|
Feb 01
2022
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,875
+2.18%
|
-
|
|
Feb 01
2022
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,050
+1.18%
|
-
|
|
Jan 03
2022
|
Kamil Ali Jackson Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,518
+6.89%
|
-
|
|
Nov 23
2021
|
Andrew Kenneth William Powell |
SELL
Bona fide gift
|
Direct |
5,500
-32.92%
|
-
|
|
Nov 01
2021
|
Foresite Capital Management Iii, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
8,276
+50.0%
|
-
|
|
Nov 01
2021
|
Foresite Capital Management Iii, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,954,904
-100.0%
|
-
|
|
Sep 01
2021
|
Joseph Monahan Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,041
-1.19%
|
$17,697
$17.22 P/Share
|
|
Sep 01
2021
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,333
+2.59%
|
-
|
|
Jul 13
2021
|
David N. Gordon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,631
-1.75%
|
$42,096
$16.98 P/Share
|
|
Jul 02
2021
|
David N. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+3.84%
|
-
|
|
Jun 03
2021
|
Kamil Ali Jackson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,492
-7.21%
|
$199,332
$21.96 P/Share
|
|
Jun 02
2021
|
Neal Walker INTERIM CEO |
SELL
Open market or private sale
|
Direct |
33,260
-1.32%
|
$698,460
$21.91 P/Share
|
|
Jun 02
2021
|
Frank Ruffo Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,037
-4.11%
|
$315,777
$21.91 P/Share
|
|
Jun 02
2021
|
Joseph Monahan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
21,790
-10.51%
|
$457,590
$21.91 P/Share
|
|
Jun 02
2021
|
Kamil Ali Jackson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
30,119
-4.96%
|
$632,499
$21.91 P/Share
|
|
Jun 02
2021
|
David N. Gordon Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
37,914
-10.8%
|
$796,194
$21.88 P/Share
|
|
Jun 01
2021
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
73,015
+5.46%
|
-
|
|
Jun 01
2021
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,189
+15.22%
|
-
|
|
Jun 01
2021
|
Joseph Monahan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+31.82%
|
-
|